Erdafitinib in Urothelial Carcinoma. Reply

Yohann Loriot; Andrea Necchi; Arlene O. Siefker-Radtke

doi:10.1056/NEJMc1911187

Erdafitinib in Urothelial Carcinoma. Reply

Yohann Loriot, Andrea Necchi, Arlene O. Siefker-Radtke

Genitourinary Medical Oncology

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	1594-1595
Number of pages	2
Journal	The New England journal of medicine
Volume	381
Issue number	16
DOIs	https://doi.org/10.1056/NEJMc1911187
State	Published - Oct 17 2019

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc1911187

Cite this

@article{f3054e0602e74ee18cf8baf9dc7e188a,

title = "Erdafitinib in Urothelial Carcinoma. Reply",

author = "Yohann Loriot and Andrea Necchi and Siefker-Radtke, {Arlene O.}",

year = "2019",

month = oct,

day = "17",

doi = "10.1056/NEJMc1911187",

language = "English (US)",

volume = "381",

pages = "1594--1595",

journal = "The New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Erdafitinib in Urothelial Carcinoma. Reply

AU - Loriot, Yohann

AU - Necchi, Andrea

AU - Siefker-Radtke, Arlene O.

PY - 2019/10/17

Y1 - 2019/10/17

UR - http://www.scopus.com/inward/record.url?scp=85073423298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073423298&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1911187

DO - 10.1056/NEJMc1911187

M3 - Letter

C2 - 31618553

SN - 0028-4793

VL - 381

SP - 1594

EP - 1595

JO - The New England journal of medicine

JF - The New England journal of medicine

IS - 16

ER -

Erdafitinib in Urothelial Carcinoma. Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this